Compare Stocks: DNLI, BEAM, HALO, and MDGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$25.39 -1.1%	$26.68	$20.23 ▼ $38.26	$2.63B	2.2	2.04 million shs	818,083 shs
DNLI Denali Therapeutics	$19.29 -3.1%	$22.77	$13.75 ▼ $27.30	$3.08B	1.02	1.71 million shs	225,403 shs
HALO Halozyme Therapeutics	$108.02 -0.3%	$104.03	$61.22 ▼ $116.85	$12.27B	0.88	1.92 million shs	172,378 shs
MDGL Madrigal Pharmaceuticals	$484.64 -1.8%	$522.03	$393.61 ▼ $615.00	$11.21B	-1.04	330,052 shs	96,342 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+4.78%	+5.94%	-13.45%	-32.30%	-0.31%
DNLI Denali Therapeutics	-0.45%	-5.10%	-10.64%	-24.33%	+29.12%
HALO Halozyme Therapeutics	-1.41%	-4.06%	-1.71%	+32.78%	+57.02%
MDGL Madrigal Pharmaceuticals	-1.16%	-4.53%	-8.77%	-9.49%	+11.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$25.39 -1.1%	$26.68	$20.23 ▼ $38.26	$2.63B	2.2	2.04 million shs	818,083 shs
DNLI Denali Therapeutics	$19.29 -3.1%	$22.77	$13.75 ▼ $27.30	$3.08B	1.02	1.71 million shs	225,403 shs
HALO Halozyme Therapeutics	$108.02 -0.3%	$104.03	$61.22 ▼ $116.85	$12.27B	0.88	1.92 million shs	172,378 shs
MDGL Madrigal Pharmaceuticals	$484.64 -1.8%	$522.03	$393.61 ▼ $615.00	$11.21B	-1.04	330,052 shs	96,342 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+4.78%	+5.94%	-13.45%	-32.30%	-0.31%
DNLI Denali Therapeutics	-0.45%	-5.10%	-10.64%	-24.33%	+29.12%
HALO Halozyme Therapeutics	-1.41%	-4.06%	-1.71%	+32.78%	+57.02%
MDGL Madrigal Pharmaceuticals	-1.16%	-4.53%	-8.77%	-9.49%	+11.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.79	Moderate Buy	$49.00	92.98% Upside
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.85	85.86% Upside
HALO Halozyme Therapeutics	2.67	Moderate Buy	$91.20	-15.57% Downside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$710.20	46.54% Upside

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, HALO, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	MDGL Madrigal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$704.00
9/24/2026	MDGL Madrigal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$704.00
9/23/2026	MDGL Madrigal Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform ➝ Buy	$725.00
9/23/2026	BEAM Beam Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/23/2026	MDGL Madrigal Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$725.00
9/9/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
9/2/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
8/31/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/25/2026	DNLI Denali Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $35.00
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/14/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$156.04M	16.81	N/A	N/A	$12.20 per share	2.08
DNLI Denali Therapeutics	$3.60M	855.43	N/A	N/A	$6.91 per share	2.79
HALO Halozyme Therapeutics	$1.40B	8.78	$4.69 per share	23.03	$0.42 per share	257.19
MDGL Madrigal Pharmaceuticals	$1.28B	8.72	N/A	N/A	$26.54 per share	18.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	32.27	11.58	0.42	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	87.32	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)

Latest DNLI, BEAM, HALO, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	BEAM Beam Therapeutics	-$1.16	N/A	N/A	N/A	$8.75 million	N/A
11/3/2026	Q3 2026	MDGL Madrigal Pharmaceuticals	-$0.8395	N/A	N/A	N/A	$404.69 million	N/A
11/2/2026	Q3 2026	HALO Halozyme Therapeutics	$2.25	N/A	N/A	N/A	$482.28 million	N/A
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.54%	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
DNLI Denali Therapeutics	0.01	8.37	8.32
HALO Halozyme Therapeutics	13.50	2.71	2.31
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
DNLI Denali Therapeutics	92.92%
HALO Halozyme Therapeutics	97.79%
MDGL Madrigal Pharmaceuticals	98.50%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
DNLI Denali Therapeutics	9.70%
HALO Halozyme Therapeutics	2.50%
MDGL Madrigal Pharmaceuticals	17.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
DNLI Denali Therapeutics	507	159.85 million	144.34 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable

DNLI, BEAM, HALO, and MDGL Headlines

Recent News About These Companies

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

2 hours ago | globenewswire.com

Madrigal Pharmaceuticals stock reports 71 percent revenue growth in Q2

October 4 at 12:32 AM | ad-hoc-news.deA

Barclays Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)

October 2, 2026 | theglobeandmail.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rated "Buy" in New Coverage at The Goldman Sachs Group

September 27, 2026 | americanbankingnews.com

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Madrigal Pharmaceuticals (MDGL)

September 25, 2026 | theglobeandmail.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Moved Up to "Strong-Buy" by The Goldman Sachs Group

September 25, 2026 | marketbeat.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to Strong-Buy at Citigroup

September 25, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 25, 2026 | americanbankingnews.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

September 25, 2026 | marketbeat.com

Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target

September 23, 2026 | marketscreener.comM

Madrigal Pharmaceuticals stock falls 1.80 percent as valuation stays high

September 22, 2026 | ad-hoc-news.deA

Madrigal Pharmaceuticals stock trades around 531 dollars as institutional interest stays strong

September 21, 2026 | ad-hoc-news.deA

Madrigal Pharmaceuticals stock holds above 530 dollars after recent ownership change

September 20, 2026 | ad-hoc-news.deA

Bank of America Corp DE Purchases Shares of 134,036 Madrigal Pharmaceuticals, Inc. $MDGL

September 20, 2026 | marketbeat.com

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - September 16, 2026

September 17, 2026 | biospace.comB

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

September 16, 2026 | globenewswire.com

Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells 5,221 Shares of Stock

September 12, 2026 | insidertrades.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 5,221 Shares

September 11, 2026 | marketbeat.com

William John Sibold Sells 6,362 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

September 11, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

Hsbc Holdings PLC Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL

September 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, HALO, and MDGL Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$25.39 -0.28 (-1.09%)

As of 10:56 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$19.29 -0.62 (-3.13%)

As of 10:56 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Halozyme Therapeutics NASDAQ:HALO

$108.02 -0.29 (-0.27%)

As of 10:56 AM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$484.64 -8.98 (-1.82%)

As of 10:56 AM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, HALO, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNLI, BEAM, HALO, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNLI, BEAM, HALO, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, HALO, and MDGL Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Denali Therapeutics NASDAQ:DNLI

Halozyme Therapeutics NASDAQ:HALO

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, HALO, and MDGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNLI, BEAM, HALO, and MDGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNLI, BEAM, HALO, and MDGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, HALO, and MDGL Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Denali Therapeutics NASDAQ:DNLI

Halozyme Therapeutics NASDAQ:HALO

Madrigal Pharmaceuticals NASDAQ:MDGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools